Impact BioMedical Inc.
IBO
$0.43
-$0.01-1.60%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.00K | 7.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.00K | 7.00K | -- | -- | -- |
| Cost of Revenue | 12.00K | 11.00K | -- | -- | -- |
| Gross Profit | 13.00K | -4.00K | -- | -- | -- |
| SG&A Expenses | 2.29M | 2.50M | 2.03M | 1.83M | 1.37M |
| Depreciation & Amortization | 1.14M | 1.13M | 1.12M | 1.12M | 1.12M |
| Other Operating Expenses | 447.00K | 383.00K | 285.00K | 173.00K | 161.00K |
| Total Operating Expenses | 4.01M | 4.17M | 3.64M | 3.40M | 3.66M |
| Operating Income | -3.99M | -4.17M | -3.64M | -3.40M | -3.66M |
| Income Before Tax | -44.21M | -38.49M | -25.02M | -24.74M | 1.10M |
| Income Tax Expenses | 33.00K | 33.00K | 33.00K | 33.00K | -- |
| Earnings from Continuing Operations | -44.24 | -38.52 | -25.05 | -24.77 | 1.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 47.00K | 48.00K | 37.00K | 62.00K | 63.00K |
| Net Income | -44.19M | -38.47M | -25.02M | -24.71M | 1.16M |
| EBIT | -3.99M | -4.17M | -3.64M | -3.40M | -3.66M |
| EBITDA | -3.13M | -4.16M | -3.63M | -3.39M | -3.66M |
| EPS Basic | -3.76 | -3.27 | -2.18 | -2.17 | 0.14 |
| Normalized Basic EPS | -0.97 | -0.66 | 0.02 | 0.02 | 0.09 |
| EPS Diluted | -3.77 | -3.59 | -2.50 | -2.49 | -0.18 |
| Normalized Diluted EPS | -0.97 | -0.86 | -0.18 | -0.17 | -0.10 |
| Average Basic Shares Outstanding | 47.94M | 47.26M | 45.07M | 43.01M | 61.00M |
| Average Diluted Shares Outstanding | 47.94M | 107.76M | 105.57M | 103.51M | 121.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |